Cargando…

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

OBJECTIVE: Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed the cost-effectiveness of once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunt, Barnaby, Malkin, Samuel J P, Moes, Robert G J, Huisman, Eline L, Vandebrouck, Tom, Wolffenbuttel, Bruce H R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777406/ https://www.ncbi.nlm.nih.gov/pubmed/31641522 http://dx.doi.org/10.1136/bmjdrc-2019-000705

Ejemplares similares

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
por: Buse, John B, et al.
Publicado: (2023)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
por: Buse, John B, et al.
Publicado: (2020)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
por: Nishimura, Erica, et al.
Publicado: (2021)

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
por: Malkin, Samuel J. P., et al.
Publicado: (2019)

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
por: Viljoen, Adie, et al.
Publicado: (2018)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11
por: Evans, Marc, et al.
Publicado: (2022)

Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands
por: Moes, Robert Gerald Jan, et al.
Publicado: (2023)

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2022)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Diabetes patient preferences for glucose-monitoring technologies: results from a discrete choice experiment in Poland and the Netherlands
por: Smith, Ian P, et al.
Publicado: (2023)

Lower extremity MRI following 10-week supervised exercise intervention in patients with diabetic peripheral neuropathy
por: Brown, Ryan, et al.
Publicado: (2021)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
por: Malkin, Samuel J. P., et al.
Publicado: (2022)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
por: Capehorn, Matthew, et al.
Publicado: (2021)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model
por: Posma, Rene A, et al.
Publicado: (2020)

Commencement of flash glucose monitoring is associated with a decreased rate of depressive disorders among persons with diabetes (FLARE-NL7)
por: Bakker, Julia J, et al.
Publicado: (2022)

Lower resource utilization for patients with healed diabetic foot ulcers during participation in a prevention program with foot temperature monitoring
por: Isaac, Adam L, et al.
Publicado: (2020)

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Shi, Fang-Hong, et al.
Publicado: (2018)

Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6)
por: Lameijer, Annel, et al.
Publicado: (2021)

Non-invasive wearables for remote monitoring of HbA1c and glucose variability: proof of concept
por: Bent, Brinnae, et al.
Publicado: (2021)

Optical coherence tomography: a novel imaging approach to visualize and quantify cutaneous microvascular structure and function in patients with diabetes
por: Argarini, Raden, et al.
Publicado: (2020)

Reducing weight and BMI following gestational diabetes: a systematic review and meta-analysis of digital and telemedicine interventions
por: Halligan, Julia, et al.
Publicado: (2021)

Impact of Ramadan fasting on glucose levels in women with gestational diabetes mellitus treated with diet alone or diet plus metformin: a continuous glucose monitoring study
por: Afandi, Bachar O, et al.
Publicado: (2017)

Engagement and outcomes in a digital Diabetes Prevention Program: 3-year update
por: Sepah, S Cameron, et al.
Publicado: (2017)

Testing the sympathetic nervous system of the foot has a high predictive value for early amputation in patients with diabetes with a neuroischemic ulcer
por: Schreuder, Sanne M, et al.
Publicado: (2018)

Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms
por: Riddy, Darren M, et al.
Publicado: (2021)

Metformin and statin use associate with plasma protein N-glycosylation in people with type 2 diabetes
por: Singh, Sunny S, et al.
Publicado: (2020)

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
por: Fritsche, Andreas, et al.
Publicado: (2019)

Unilateral remote temperature monitoring to predict future ulceration for the diabetic foot in remission
por: Lavery, Lawrence A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tblj6h84bmpcp34gtt9ee40bvg